Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL790024 | 1.00 | TSHR (0.39) | TSHRCA12CA14SMN1; SMN2HCAR2 | |
| SCHEMBL790105 | 1.00 | TSHR (0.39) | TSHRCA12CA14SMN1; SMN2HCAR2 | |
| SCHEMBL18649396 | 0.87 | TSHR (0.36) | TSHRCA12CA14SMN1; SMN2 | |
| SCHEMBL19764851 | 0.84 | TSHR (0.37) | TSHRCA12HCAR2CA9CA1 | |
| SCHEMBL22503374 | 0.83 | — | — | |
| SCHEMBL18879824 | 0.83 | — | — | |
| SCHEMBL13808473 | 0.81 | CA14 (0.56) | TSHRCA12CA14SMN1; SMN2CA9 | |
| SCHEMBL13197416 | 0.81 | CA14 (0.56) | TSHRCA12CA14SMN1; SMN2CA9 | |
| SCHEMBL10289198 | 0.81 | CA14 (0.56) | TSHRCA12CA14SMN1; SMN2CA9 | |
| SCHEMBL18474777 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Pharmaceuticals, Inc. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210179656-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210139523-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210106604-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2021-04-15 | — | — | US | disclosed |
| US-10793591-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10780105-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-20150105341-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-04-16 | — | — | US | disclosed |
| US-20150051167-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2015-02-19 | — | — | US | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
| US-20150005251-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV | 2015-01-01 | — | — | US | disclosed |
| US-8871737-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | TSHR 2960/4885CA12 4861/4885CA14 4746/4885 |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | TSHR 2960/4885CA12 4861/4885CA14 4746/4885 |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | TSHR 2960/4885CA12 4861/4885CA14 4746/4885 |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | TSHR 3355/4885CA12 4763/4885CA14 4206/4885 |
| US-20150051167-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | TSHR 3355/4885CA12 4763/4885CA14 4206/4885 |
| US-20150105341-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | TSHR 2312/4885CA12 4814/4885CA14 4656/4885 |
| US-20210179656-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | TSHR 3355/4885CA12 4763/4885CA14 4206/4885 |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | TSHR 2346/4885CA12 4862/4885CA14 4763/4885 |
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | PNP, RNGTT, NT5C3B | TSHR 3939/4885CA12 1877/4885CA14 1941/4885 |
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, TYMP, SLC29A1 | TSHR 3061/4885CA12 3264/4885CA14 2317/4885 |
| US-20210139523-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | TSHR 2960/4885CA12 4861/4885CA14 4746/4885 |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | TSHR 3446/4885CA12 4443/4885CA14 3689/4885 |
| US-10780105-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C3B | TSHR 2178/4885CA12 4811/4885CA14 4417/4885 |
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, TYMP, SLC29A1 | TSHR 3061/4885CA12 3264/4885CA14 2317/4885 |
| US-20150005251-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NT5C2 | TSHR 3730/4885CA12 4747/4885CA14 3921/4885 |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | TSHR 4075/4885CA12 4822/4885CA14 4664/4885 |
| US-10793591-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C2 | TSHR 2960/4885CA12 4861/4885CA14 4746/4885 |
| US-20210106604-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | TSHR 2178/4885CA12 4811/4885CA14 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.